Loading…
Merck & Co., Inc. is projected to rise to $170.00 by 2027, a +30% move from its current price of $130.76. MRK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 29 | $128.78 | $130.82 | $132.90 | +0.05% |
| Jul 30 | $128.00 | $130.89 | $133.84 | +0.10% |
| Jul 31 | $127.42 | $130.95 | $134.58 | +0.15% |
| Aug 1 | $126.95 | $131.02 | $135.22 | +0.20% |
| Aug 2 | $126.54 | $131.08 | $135.79 | +0.25% |
| Aug 3 | $126.18 | $131.15 | $136.32 | +0.30% |
| Aug 4 | $125.85 | $131.21 | $136.81 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $125.85 | $131.21 | $136.81 | +0.35% |
| Week 2 | $124.12 | $131.67 | $139.68 | +0.70% |
| Week 3 | $122.91 | $132.13 | $142.03 | +1.05% |
| Week 4 | $121.97 | $132.59 | $144.13 | +1.40% |
| Week 5 | $121.19 | $133.05 | $146.06 | +1.75% |
| Week 6 | $120.54 | $133.51 | $147.88 | +2.10% |
| Week 7 | $119.97 | $133.97 | $149.62 | +2.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Co., Inc. (MRK) is a global healthcare company with a broad portfolio spanning human health pharmaceuticals and veterinary products. It is currently priced at $131.07 with a market cap of $323.72B and ranks 38. This positioning reflects a large, established presence in the sector and a history of diverse product lines.
A major floor 17.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.2% away) — a breakout level to watch.
A major ceiling 8.9% above — clearing it would confirm fresh momentum.
Key MRK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $129.21 | Buy | $129.45 | Buy |
| MA 10 | $127.00 | Buy | $128.02 | Buy |
| MA 20 | $126.85 | Buy | $126.24 | Buy |
| MA 50 | $121.45 | Buy | $122.65 | Buy |
| MA 100 | $118.73 | Buy | $118.73 | Buy |
| MA 200 | $110.71 | Buy | $112.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.24 | Neutral |
| Stoch RSI (14) | 95.24 | Sell |
| CCI (20) | 114.82 | Buy |
| Williams %R (14) | -3.01 | Info |
| MACD (12,26,9) | 0.32 | Buy |
| ROC (12) | 4.55 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 96.99 | Sell |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | 5.55 | Buy |
| Ultimate (7,14,28) | 61.79 | Neutral |
| Momentum (10) | 6.73 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 131.48 | Sell |
| ADX (14) | 15.92 | Neutral |
| ATR (14) | 1.90 | Info |
Technically, the near term shows a bullish tilt with the stock momentum supported by key levels. RSI14 is 60, and the price trades above the SMA50 of $120.72 and above the SMA200 of $110.28, signaling constructive momentum. The stock sits on support at $113.87 and faces resistance at $130.48, with a 30-day range of $117.37 to $146.37.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $106.45 | $130.76 | $178.17 | 0% | Neutral | |
| $139.37 | $170.00 | $216.72 | +30% | Bullish | |
| $162.79 | $202.35 | $265.02 | +55% | Bullish | |
| $187.45 | $236.63 | $316.57 | +81% | Bullish | |
| $192.94 | $246.86 | $336.25 | +89% | Bullish | |
| $207.94 | $269.31 | $372.66 | +106% | Bullish | |
| $224.42 | $293.95 | $412.56 | +125% | Bullish | |
| $242.38 | $320.82 | $456.14 | +145% | Bullish | |
| $299.82 | $400.81 | $576.70 | +207% | Bullish | |
| $323.65 | $436.78 | $635.46 | +234% | Bullish | |
| $445.38 | $626.94 | $955.96 | +379% | Bullish | |
| $823.09 | $1,242.70 | $2,031.37 | +850% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $106.45 | $130.76 | $153.69 | +0.00% |
| August 2026 | $116.60 | $136.05 | $161.85 | +4.05% |
| September 2026 | $116.60 | $136.81 | $164.23 | +0.55% |
| October 2026 | $117.38 | $138.33 | $167.27 | +1.12% |
| November 2026 | $121.25 | $143.43 | $174.47 | +3.69% |
| December 2026 | $122.74 | $145.69 | $178.17 | +1.58% |
Click any year to see its month-by-month MRK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MRK is projected to trade between $106.45 and $178.17, averaging $130.76 — a potential gain of 0% from today's $130.76. A consolidation phase looks the most probable path here.
Merck & Co., Inc.'s 2027 outlook centres on $170.00, within a $139.37 to $216.72 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2028, MRK could reach as high as $265.02, with a base case around $202.35 and support toward $162.79 — roughly +55% from $130.76. Buyers look set to stay in control over this stretch.
Expect MRK to range from $187.45 to $316.57 through 2029. The $236.63 average target implies a +81% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The MRK price prediction for 2030 points to an average of $246.86 (low $192.94, high $336.25) — a potential gain of +89% on today's $130.76. Buyers look set to stay in control over this stretch.
In 2031, MRK is projected to trade between $207.94 and $372.66, averaging $269.31 — a potential gain of +106% from today's $130.76. That is up +9% on the projected 2030 average. Momentum favours further upside here.
Merck & Co., Inc.'s 2032 outlook centres on $293.95, within a $224.42 to $412.56 range. That is up +9% on the projected 2031 average. That marks a +125% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MRK could reach as high as $456.14, with a base case around $320.82 and support toward $242.38 — roughly +145% from $130.76. Momentum favours further upside here.
Expect MRK to range from $299.82 to $576.70 through 2034. The $400.81 average target implies a +207% move from current prices. That is up +25% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MRK price prediction for 2035 points to an average of $436.78 (low $323.65, high $635.46) — a potential gain of +234% on today's $130.76. Momentum favours further upside here.
In 2040, MRK is projected to trade between $445.38 and $955.96, averaging $626.94 — a potential gain of +379% from today's $130.76. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Merck & Co., Inc.'s 2050 outlook centres on $1,242.70, within a $823.09 to $2,031.37 range. That is up +98% on the projected 2040 average. That marks a +850% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MRK today (≈ 7.647599 MRK) could be worth
$9,503.64
+$8,503.64 (+850%) by 2050 · US Dollar
Based on the average projected MRK price of $1,242.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRKwould be worth at today's price.
$1,000 invested in MRK on Jul 28, 2025 (≈ 11.896265 MRK) would be worth
$1,555.56
+$555.56 (+55.6%) today · 1.56× · US Dollar
Based on a MRK entry price of $84.06 vs. today's $130.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $124.4 | $1,051.13 | +5.1% |
| 1 month ago | $128.66 | $1,016.32 | +1.6% |
| 3 months ago | $110.03 | $1,188.4 | +18.8% |
| 6 months ago | $106.9 | $1,223.2 | +22.3% |
| 1 year ago | $84.06 | $1,555.56 | +55.6% |
| All time (5.0y) ago | $76.93 | $1,699.73 | +70.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRK forecast.
Our base-case forecast reaches $260.00 around 2031.
Implied market cap at $260.00: $642.15B
The multi-year forecast shows continued upside with a clear progression in annual averages. The 2026 forecast lists min $106.45, avg $131.07, max $178.52 with ROI 0 and NEUTRAL sentiment. By 2027 the avg rises to $170.28 (min $139.59, max $217.09) with ROI 29.9 and a BULLISH tone, followed by 2028 avg $202.74 (min $163.09, max $265.55) ROI 54.7 and BULLISH.
The 2029 forecast shows avg $236.76 (min $187.55, max $316.76) ROI 80.6 and BULLISH, and 2030 avg $246.93 (min $192.99, max $336.37) ROI 88.4 and BULLISH. For 2040 the forecast is avg $626.07 (min $444.75, max $954.66) ROI 377.7 and BULLISH, and for 2050 avg $1,237.75 (min $819.80, max $2,023.33) ROI 844.3 and BULLISH. These are estimates, not guarantees, and reflect bullish longer-term upside with substantial potential dispersion.
Tap a question to reveal the answer.
Avg $246.93; Min $192.99; Max $336.37; ROI 88.4; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with 2027 avg $170.28 and 2030 avg $246.93, 2040 avg $626.07, and 2050 avg $1,237.75. These are estimates, not guarantees.
The 2050 forecast shows avg $1,237.75 and max $2,023.33, indicating potential for strong upside by 2050. This is not a guarantee.
The 30-day range is $117.37 to $146.37.
Current price $131.07; Market cap $323.72B; Rank 38.
Merck & Co., Inc. Community Discussion
0Share your Merck & Co., Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.